Valion Bio (VBIO) Stock Price, News & Analysis
Company Description
Valion Bio, Inc. develops immunotherapeutic biologics based on Toll-like receptor 5, or TLR5, activation for cytoprotection and immune modulation. The company, formerly known as Tivic Health Systems, Inc., trades on Nasdaq under the symbol VBIO and operates as a clinical-stage biopharmaceutical company. Its lead program is Entolimod™, a TLR5 agonist being developed for Acute Radiation Syndrome, oncology supportive care, and longevity-related indications.
Entolimod is designed to activate innate immune pathways, including cytoprotective signaling relevant to bone marrow and gastrointestinal tissue preservation after ionizing radiation exposure. The Acute Radiation Syndrome program is positioned as a medical countermeasure for radiological threats, and the company has described FDA Fast Track and Orphan Drug designations for Entolimod in ARS. Valion Bio also links Entolimod's mechanism to oncology supportive care, including potential treatment of neutropenia, a condition commonly associated with chemotherapy, and lymphocyte exhaustion, a state of T-cell dysfunction.
The company's pipeline also includes Entolasta™, a next-generation TLR5 agonist intended to broaden the therapeutic reach of the same innate-immunity platform. Entolasta provides additional pipeline depth in areas that include oncology supportive care and other applications where TLR5-mediated immune modulation may be relevant.
Pipeline and manufacturing model
Valion Bio combines drug development with internal biomanufacturing capabilities through Velocity Bioworks, its wholly owned contract development and manufacturing organization. Velocity Bioworks provides biomanufacturing services to third-party biotechnology companies and also supports Valion Bio's own biologics pipeline. This structure gives the company an operating model that includes clinical-stage therapeutic development and CDMO service activity within the same corporate group.
The company is headquartered in San Antonio, Texas. Its current corporate identity reflects a completed rebranding from Tivic Health Systems to Valion Bio, with the ticker change to VBIO effective in April 2026. The name change marks the company's stated transition from its prior health-technology identity to a biopharmaceutical platform centered on Entolimod, Entolasta, innate immunity, and biologics manufacturing.
Stock Performance
Valion Bio (VBIO) stock last closed at $0.1590. At a market capitalization of $660.0K, VBIO is classified as a micro-cap stock with approximately 22.2M shares outstanding.
VBIO Rankings
Latest News
Valion Bio has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include clinical trial, earnings. View all VBIO news →
SEC Filings
Valion Bio has filed 5 recent SEC filings, including 2 Form SCHEDULE 13D/A, 1 Form RW, 1 Form 8-K/A, 1 Form 8-K. The most recent filing was submitted on August 24, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all VBIO SEC filings →
Financial Highlights
operating income reached -$7.9M, and net income was -$8.9M. The company generated -$7.0M in operating cash flow. With a current ratio of 20.13, the balance sheet reflects a strong liquidity position.
Upcoming Events
Top-line therapeutic data
Ukraine regulatory decision
First patient enrollment
Ukraine regulatory decision
Interim readout
Topline data release
Valion Bio has 6 upcoming scheduled events. The next event, "Top-line therapeutic data", is scheduled for September 1, 2026 (in 5 days). Investors can track these dates to stay informed about potential catalysts that may affect the VBIO stock price.
Short Interest History
Short interest in Valion Bio (VBIO) currently stands at 837.9 thousand shares, up 217.5% from the previous reporting period, representing 3.8% of the float. Since April 2026, short interest has increased by 240.9%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Valion Bio (VBIO) currently stands at 1.0 days, down 23.7% from the previous period. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The ratio has shown significant volatility over the period, ranging from 1.0 to 2.0 days.
VBIO Company Profile & Sector Positioning
Valion Bio (VBIO) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ.